fashion -WSS

fashion

author：fashion 2025-09-27 06:09:39 - browse：68282

The future looks even brighter for the blockbuster Enhertu, showcased here at ASCO. ADAM FEUERSTEIN/STAT

CHICAGO — The cancer drug Enhertu stalled the growth of tumors by more than a year, significantly longer than standard chemotherapy did in women with the most common form of metastatic breast cancer — a clinical trial result that once again promises to rewrite the rules for the treatment of the disease.

The makers of Enhertu, Daiichi Sankyo and AstraZeneca, said the new data, if cleared by regulators, could shift the way physicians treat hormone receptor-positive, metastatic breast cancer, and create a new standard of care in which patients with breast tumors that express even the faintest amount of HER2 protein can benefit.

“It’s not an overestimation to say that trastuzumab deruxtecan is the most potent drug ever developed for breast cancer,” said Paolo Tarantino, a medical oncologist at the Dana-Farber Cancer Institute, using the scientific name for Enhertu. “It does come with side effects that we’re learning to manage, but with that said, I’ve never seen data like what’s being reported here.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： In Spain, a hospital brews its own CAR

WSS

FDA reorg will put new emphasis on investigations, sources say

Medical school prerequisites are outdated

Ohio still needs to do more to protect the right to abortion

SNAP should offer more nutrition education

Keeping primary care docs in field isn't impossible, says AAFP CEO

Christmas in the PICU brings some surprising joy

focus

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Guidelines to prevent youth baseball injuries need more muscle

A letter from the executive editor: STAT UnitedHealth investigation

Walensky prepares to leave CDC — and Congress — behind

Readout Newsletter: Novo Nordisk trial, Verve base editing, etc

Trump demands the U.S. pay no more for drugs than other countries … again

Today's health inequities arise from racist U.S. history, say experts

Trump demands the U.S. pay no more for drugs than other countries … again

Type 2 diabetes prevention programs work at large scale: study

Walensky prepares to leave CDC — and Congress — behind

Medicare drug price negotiation hasn't dried up venture capital

leisure time

White House drug czar issues call for 'recovery

How state and local governments are sidelining science

How to keep neuroscience’s past racism from being its future

Why health records don't always know when patients are dead

Albert Bourla of Pfizer: worst biopharma CEO of 2023

Experimental asthma app from Apple and Anthem shows promise

focus

leisure time

entertainment

hotspot